Clarivate PLC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NYSE
CLVT
Clarivate PLCClarivate Plc announced the appointment of Michael Easton as its new Executive Vice President & Chief Financial Officer, effective August 8, 2026, succeeding Jonathan Collins.
NYSE
CLVT
Clarivate PLCClarivate Plc announced its second quarter 2026 financial results, reporting a net loss of $268.6 million, primarily due to a significant non-cash goodwill impairment charge, while reaffirming its full-year financial outlook.
NYSE
CLVT
Clarivate PLCClarivate Plc announced a definitive agreement to sell its Life Sciences and Healthcare business to an affiliate of Altaris, LLC for $600 million.
NYSE
CLVT
Clarivate PLCClarivate Plc has appointed former CPA Global CEO Simon Webster as President of its Intellectual Property segment, succeeding Maroun S. Mourad.
NYSE
CLVT
Clarivate PLCClarivate Plc shareholders approved all proposals at the 2026 Annual General Meeting, including director elections and executive compensation.
NYSE
CLVT
Clarivate PLCClarivate Plc announced its first quarter 2026 financial results, showing progress on its Value Creation Plan and reaffirming its full-year financial outlook.
NYSE
CLVT
Clarivate PLCClarivate Plc has adopted an Amended and Restated Executive Severance Plan, expanding eligibility and modifying equity vesting terms for executives, particularly in change-of-control scenarios.
NYSE
CLVT
Clarivate PLCClarivate Plc reported strong fourth quarter and full year 2025 results, exceeding financial guidance, and announced plans to sell its Life Sciences & Healthcare business to sharpen strategic focus.
NYSE
CLVT
Clarivate PLCClarivate PLC announced it has posted a video webinar titled 'Intelligence Amplified in the Age of AI' along with related presentation materials to its investor relations website.
NYSE
CLVT
Clarivate PLCClarivate Plc announced the full redemption of its remaining $100 million senior secured notes due 2026 and significant share repurchases in 2025, signaling a focus on debt reduction and shareholder returns.
NYSE
CLVT
Clarivate PLCClarivate Plc reported improved Q3 2025 net loss and raised its full-year revenue guidance, driven by organic ACV growth and strategic initiatives.
NYSE
CLVT
Clarivate PLCClarivate PLC and its subsidiaries amended their credit agreement, increasing total revolving credit commitments by $75 million to an aggregate of $775 million.
NYSE
CLVT
Clarivate PLCClarivate Plc has announced a leadership transition in its Intellectual Property segment, with Gordon Samson departing and Maroun S. Mourad appointed as the new President, alongside a board resignation.
NYSE
CLVT
Clarivate PLC8-K: Clarivate Reports Mixed Q2 2025 Results Amid Strategic Divestitures and Organic Growth Acceleration
Clarivate Plc announced second quarter 2025 results showing improved net loss and positive organic revenue growth, despite overall revenue declines due to strategic divestitures, while reaffirming its full-year 2025 outlook.
NYSE
CLVT
Clarivate PLCClarivate Plc announced the election of Kenneth Cornick, co-founder and former President and CFO of Clear Secure, Inc., to its Board of Directors, increasing the board size to eleven members.
NYSE
CLVT
Clarivate PLCClarivate Plc has successfully completed a refinancing transaction, securing a new $500 million incremental term loan maturing in 2031, and using the proceeds to redeem the majority of its 4.50% Senior Secured Notes due 2026.
NYSE
CLVT
Clarivate PLCClarivate Plc's subsidiary, Camelot Finance S.A., plans to redeem $500 million of its 4.50% Senior Secured Notes due 2026, contingent on successful debt financing.
NYSE
CLVT
Clarivate PLCClarivate Plc held its 2025 Annual General Meeting where shareholders approved all proposals, including the election of directors, executive compensation, auditor ratification, an incentive award plan, and authorization for share repurchases.
NYSE
CLVT
Clarivate PLCClarivate Plc reports a slight decrease in total revenue for Q1 2025, but reaffirms its 2025 outlook, citing accelerated recurring organic revenue growth and strategic share repurchases.
NYSE
CLVT
Clarivate PLCMichael J. Angelakis will retire from Clarivate PLC's Board of Directors effective upon the re-election of board members at the 2025 Annual General Meeting of Shareholders.
NYSE
CLVT
Clarivate PLCClarivate's Q4 2024 results show a slight revenue decrease but improved net loss, while the company initiates a strategic review including potential divestitures.
NYSE
CLVT
Clarivate PLCClarivate's Board of Directors has authorized a new $500 million share repurchase program, replacing the existing program and signaling confidence in the company's growth prospects.
NYSE
CLVT
Clarivate PLCClarivate Plc has amended the retirement date of board member Richard Roedel from December 31, 2024, to January 1, 2025.
NYSE
CLVT
Clarivate PLCClarivate's third quarter results were disappointing, with a 3.9% revenue decrease and a net loss of $65.6 million, leading to the removal of their 2024 financial outlook.
NYSE
CLVT
Clarivate PLCClarivate has announced the appointment of Matti Shem Tov as its new CEO, succeeding Jonathan Gear, effective August 9, 2024.
NYSE
CLVT
Clarivate PLCClarivate's second quarter results show a revenue decrease, but the company reaffirms its 2024 outlook and anticipates a return to organic growth in the second half of the year.
NYSE
CLVT
Clarivate PLCClarivate PLC announces the retirement of director Richard Roedel due to health reasons, with Valeria Alberola set to take over as Audit Committee Chair.
NYSE
CLVT
Clarivate PLCClarivate Plc successfully held its 2024 Annual General Meeting, electing directors and approving executive compensation and auditor ratification.
NYSE
CLVT
Clarivate PLCClarivate's first quarter results show a slight revenue decrease and a net loss, but the company reaffirms its 2024 outlook.
NYSE
CLVT
Clarivate PLCClarivate has entered into an investment agreement with Exor N.V., resulting in a board seat for Exor's Chief Operating Officer and certain standstill restrictions for Exor.